Allscripts, Misys clear antitrust hurdle
CHICAGO The clinical software company Allscripts has announced that its merger deal with Misys Healthcare, a software applications company, has passed one hurdle by clearing the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
The deal was announced back on March 18 and it was said then that the new company, Allscripts-Misys Healthcare Solutions would have a client base of 150,000 physicians.
Under the terms of the agreement, which were approved by the board of directors of both companies, Misys Healthcare will be merged with a wholly-owned subsidiary of Allscripts, and Misys Plc, the owner of Misys Healthcare, will contribute $330 million in cash to Allscripts, for which it will receive shares representing a 54.5 percent ownership position in the combined company.
FDA issues third approvable letter for Wyeth’s bazedoxifene
WASHINGTON Wyeth Pharmaceuticals’ new drug for treating postmenopausal osteoporosis has hit another speed bump.
The Food and Drug Administration sent a third approvable letter to Wyeth for the drug bazedoxifene pending analyses about the incidence of stroke and venal thrombosis in patients who use it. The FDA made a similar request in a letter sent in December.
Merck reported that its postmenopausal osteoporosis drug Fosamax (alendronate sodium) had worldwide sales of $3.05 billion in 2007.
Longs plans drive-through windows at Hawaiian locations
NEW YORK Longs Drug Stores plans to open drive-through windows at some of its stores in Hawaii, the company announced recently.
The drugstore chain, based in Walnut Creek, Calif., will add a drive-through window to its store in Maui later this year. The new store it plans to open in Honolulu will also have a window.
Walgreens, which recently opened its first locations in Hawaii, credits itself with inventing the concept of the drugstore with a drive-through pharmacy more than 15 years ago.